Global Biologics Safety Testing market is anticipated to reach USD 3.5 billion in 2021 growing at a CAGR of 12.5% during the forecasting period, 2021-2028.
A biologic drug is produced by a living organism or is a component of it. Biologic safety testing are conducted on drugs, therapeutics, stem or tissue cell and other derived products. These tests are performed so as to ensure that the products are contamination free. There are multiple types of biologics like vaccine, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins.
Due to an increased RnD in biopharmaceutical sector along with raising concerns over cell contamination and growth of the market of biosimilar and biologics are some of the factors that have supported long-term expansion for Biologics Safety Testing industry.
Global Biologics Safety Testing market is segmented into Product & Service, Application, Test Type and, geography.
Product & Service segment is segmented into Consumables, Instrument, and Services
Application segment is segmented into Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products
Test Type segment is segmented into Endotoxin, Myoplasm, and Sterility Test
Geographically, global Biologics Safety Testing market is sub segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America and insights are provided for each region and major countries within the regions
Key players in global Biologics Safety Testing market are Maravai Lifesciences (US), Associates of Cape Cod, Inc. (US), bioMérieux SA (France), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Nelson Laboratories, LLC (US), Bio-Rad Laboratories, Inc. (US) and QIAGEN (Germany), Agilent Technologies, Inc. (US), Pacific BioLabs (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), FUJIFILM Wako Pure Chemical Corporation (Japan), and Almac Group (UK). Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), and Eurofins Scientific (Luxembourg) among others.
|
Report Feature |
Descriptions |
|---|---|
|
Market Revenue In 2021 |
USD 3.5 billion |
|
Growth Rate |
CAGR of 12.5% during the forecasting period, 2021-2028 |
|
Historical Data |
2018-2019 |
|
Forecast Years |
2021-2028 |
|
Base Year |
2020 |
|
Units Considered |
Revenue in USD billion and CAGR from 2021 to 2028 |
|
Report Segmentation |
Product & Service, Application, Test Type and Geography |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
Maravai Lifesciences (US), Associates of Cape Cod, Inc. (US), bioMérieux SA (France), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Nelson Laboratories, LLC (US), Bio-Rad Laboratories, Inc. (US) and QIAGEN (Germany), Agilent Technologies, Inc. (US), Pacific BioLabs (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), FUJIFILM Wako Pure Chemical Corporation (Japan), and Almac Group (UK). Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), and Eurofins Scientific (Luxembourg) |
|
Available Customization |
In addition to the market data for Biologics Safety Testing market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement. |
.png)
.png)
.png)
.png)
.png)
.png)